Running Oak Capital LLC Sells 6,781 Shares of STERIS plc $STE

Running Oak Capital LLC lessened its holdings in shares of STERIS plc (NYSE:STE) by 10.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 60,038 shares of the medical equipment provider’s stock after selling 6,781 shares during the period. STERIS makes up 1.9% of Running Oak Capital LLC’s investment portfolio, making the stock its 19th largest position. Running Oak Capital LLC’s holdings in STERIS were worth $15,221,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of STERIS by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 12,213,521 shares of the medical equipment provider’s stock valued at $3,022,114,000 after buying an additional 50,393 shares in the last quarter. State Street Corp boosted its holdings in shares of STERIS by 4.0% during the 3rd quarter. State Street Corp now owns 4,354,839 shares of the medical equipment provider’s stock valued at $1,077,564,000 after buying an additional 166,736 shares in the last quarter. Orbis Allan Gray Ltd boosted its holdings in shares of STERIS by 36.0% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after buying an additional 556,088 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of STERIS by 16.4% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock valued at $387,797,000 after buying an additional 221,199 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of STERIS by 4.9% in the 3rd quarter. Invesco Ltd. now owns 1,280,142 shares of the medical equipment provider’s stock worth $316,758,000 after purchasing an additional 59,443 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

Insiders Place Their Bets

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the transaction, the director owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.07% of the company’s stock.

STERIS Price Performance

STE opened at $222.43 on Monday. The stock has a 50-day moving average price of $234.47 and a 200-day moving average price of $246.79. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The firm has a market cap of $21.81 billion, a PE ratio of 31.02 and a beta of 1.07. STERIS plc has a 1 year low of $209.98 and a 1 year high of $269.44.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The company’s revenue was up 9.2% compared to the same quarter last year. During the same period last year, the firm posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Sell-side analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th were given a $0.63 dividend. The ex-dividend date of this dividend was Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.1%. STERIS’s payout ratio is 35.15%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on STE shares. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and an average price target of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.